Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Clear all
Terminated Phase 2 Interventional Results available

99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

NCT03232580
View directory record Official record
Conditions
Spondyloarthritis
Interventions
rhAnnexin V-128
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 25, 2026, 5:44 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Fontana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 5:44 PM EDT
Completed No phase listed Observational

PET/CT in Psoriatic Arthritis

NCT01654198
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
FDG-PET/CT scan
Radiation
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 25, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Results available

Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice

NCT01147874
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
lab draws and imaging
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Dallas, Texas • Houston, Texas • Webster, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 25, 2026, 5:44 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Sonelokimab, Placebo
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 5:44 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

ASIS for Enbrel in Plaque Psoriasis

NCT02112097
View directory record Official record
Conditions
Plaque Psoriasis.
Interventions
Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36
Drug
Lead sponsor
ASIS Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 25, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

NCT00763555
View directory record Official record
Conditions
Psoriasis
Interventions
CD 2027, Calcitriol Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Fridley, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 25, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Fluphenazine Hydrochloride for Psoriasis

NCT00929578
View directory record Official record
Conditions
Psoriasis
Interventions
Fluphenazine, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 25, 2026, 5:44 PM EDT
Recruiting Phase 3 Interventional

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

NCT07286058
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
19
States / cities
Tucson, Arizona • Fountain Valley, California • La Mesa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 5:44 PM EDT
Not listed Phase 4 Interventional

A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis

NCT01558310
View directory record Official record
Conditions
Scalp Psoriasis, Plaque Psoriasis
Interventions
Ustekinumab, Placebo
Drug
Lead sponsor
Paul Steven Yamauchi, MD, PhD
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Oct 25, 2026, 5:44 PM EDT
Not listed Not applicable Interventional

Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis

NCT02447068
View directory record Official record
Conditions
Psoriasis
Interventions
Luma Light System, Luma Light, Occlusive Dressing
Device
Lead sponsor
Illumicure Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 25, 2026, 5:44 PM EDT
Completed No phase listed Observational

An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers

NCT03964168
View directory record Official record
Conditions
Psoriasis
Interventions
Biologic Agent
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
3 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 25, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

NCT03022617
View directory record Official record
Conditions
Psoriatic Nail, Psoriasis Vulgaris, Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 25, 2026, 5:44 PM EDT
Completed No phase listed Observational

Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

NCT05513014
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 25, 2026, 5:44 PM EDT
Completed Phase 1 Interventional

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

NCT07340216
View directory record Official record
Conditions
Psoriasis
Interventions
ARQ-154 Foam 0.3%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Bryant, Arkansas • Miami Lakes, Florida • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 5:44 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Regulation of Inflammatory Genes in Psoriasis

NCT03125655
View directory record Official record
Conditions
Psoriasis, Inflammation
Interventions
Inflammatory markers
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 25, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

NCT01882647
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
000-0551 Lotion, Vehicle Lotion
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Brandon, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 25, 2026, 5:44 PM EDT
Terminated Phase 1 Interventional

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

NCT06005792
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
XmAb27564, Placebo
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Sherman Oaks, California • Thousand Oaks, California • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 25, 2026, 5:44 PM EDT
Not listed Phase 4 Interventional

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

NCT01939132
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Open label H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Oct 25, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis

NCT04269993
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis
Interventions
Cannabis: placebo and medium THC/medium CBD
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 25, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

NCT05375955
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 25, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

NCT01700985
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
122-0551, Vehicle
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Diego, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 25, 2026, 5:44 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 25, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Results available

Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis

NCT01111123
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%), Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 25, 2026, 5:44 PM EDT